Trial ID or NCT#



not recruiting iconNOT RECRUITING


This is an open‑label non‑randomized two‑center phase 2 study evaluating the safety and efficacy of concurrent therapy with ibrutinib and venetoclax in subjects with relapsed or refractory CLL/SLL.

Official Title

An Open Label Phase 2 Trial of Venetoclax With Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


David Iberri
David Iberri
Hematologist, Medical oncologist
Clinical Assistant Professor, Medicine - Hematology
Steven Coutre
Steven Coutre
Hematologist, Leukemia specialist
Professor of Medicine (Hematology) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.


(650) 498-7061